BridgeBio Pharma (BBIO) total liabilities

Total liabilities · fiscal 2025
$3.01B

BridgeBio Pharma (BBIO) had total liabilities of $3.01B at the end of fiscal 2025 (December 31, 2025). That is 26.7% higher than the $2.38B of fiscal 2024. Figures as of 19 Nov 2026, 01:39 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$3.01B
Change on fiscal 2024
+26.7%
Growth, 5 years
+38.3% a year
Highest on record
$3.01Bfiscal 2025
Lowest on record
$87.58Mfiscal 2018
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BridgeBio Pharma total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 38.3% a year. Across the 8 fiscal years on record (2018–2025), the highest was $3.01B in fiscal 2025 and the lowest $87.58M in fiscal 2018.

History · 8 fiscal years

Total liabilities by fiscal year

BridgeBio Pharma total liabilities, year by year

BridgeBio Pharma (BBIO) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$3.01B 26.7% up
2024$2.38B 25.8% up
2023$1.89B 1.1% up
2022$1.87B 0.6% down
2021$1.88B 215.3% up
2020$595.70M 282.6% up
2019$155.70M 77.8% up
2018$87.58M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of BridgeBio Pharma and comparable companies
CompanyTotal liabilitiesFiscal year
ICON ICLR$7.08B2025
Jazz Pharmaceuticals JAZZ$7.34B2025
Solventum SOLV$9.24B2025
BridgeBio Pharma BBIO$3.01B2025
Summit Therapeutics SMMT$92.32M2025
Glaukos GKOS$237.33M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma total liabilities: questions and answers

How large are BridgeBio Pharma's total liabilities?

BridgeBio Pharma (BBIO) had total liabilities of $3.01B at the end of fiscal 2025 (December 31, 2025). That is 26.7% higher than the $2.38B of fiscal 2024.

What is the growth rate of BridgeBio Pharma's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 38.3% a year.

What are the highest and lowest total liabilities figures on record for BridgeBio Pharma?

Across the 8 fiscal years on record (2018–2025), the highest was $3.01B in fiscal 2025 and the lowest $87.58M in fiscal 2018.

How is BridgeBio Pharma's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For BridgeBio Pharma it is on record here for 8 fiscal years, 2018 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/BBIO/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.